| Carolyn Kelly, DPM | |
|
396 Remington Blvd Ste 370, Bolingbrook, IL 60440-4302 | |
| (630) 418-6601 | |
| (630) 312-2223 |
| Full Name | Carolyn Kelly |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 13 Years |
| Location | 396 Remington Blvd Ste 370, Bolingbrook, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619264041 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| John H Stroger Jr Hospital | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cook County | 2860398088 | 619 |
News Archive
Tobacco-related disease kills more people worldwide than any other single factor. To help address this problem, the University of California, Riverside has received six grants from the University of California Tobacco-Related Disease Research Program (TRDRP), the most TRDRP grants the campus has received in any year.
Record numbers of soldiers are returning from Iraq and Afghanistan with serious spinal cord injuries (SCI). Medical advancements can help heal their physical wounds, but little is known about how these veterans re-engage with their communities and rebuild meaningful lives. "How do they transition back to family and community life? How do they adjust to their physical impairments? And how do they reconfigure their homes, their work and their lives?" asked Cathy Lysack, professor of occupational therapy and gerontology at Wayne State University.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
Tyler Wertz, 18, and his 16-year old brother Austin Tucker, fight, tease, love and support each other like most brothers do. Unlike most brothers, however, they share the same uncertain future—both have heart assist devices keeping them alive while they struggle with a debilitating disease. As young boys, Tyler and Austin were diagnosed with Becker's Muscular Dystrophy, a disease that slowly weakens the arms and legs and damages the heart.
› Verified 8 days ago
| Provider Name | Cook County |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588612832 PECOS PAC ID: 2860398088 Enrollment ID: O20031209000747 |
News Archive
Tobacco-related disease kills more people worldwide than any other single factor. To help address this problem, the University of California, Riverside has received six grants from the University of California Tobacco-Related Disease Research Program (TRDRP), the most TRDRP grants the campus has received in any year.
Record numbers of soldiers are returning from Iraq and Afghanistan with serious spinal cord injuries (SCI). Medical advancements can help heal their physical wounds, but little is known about how these veterans re-engage with their communities and rebuild meaningful lives. "How do they transition back to family and community life? How do they adjust to their physical impairments? And how do they reconfigure their homes, their work and their lives?" asked Cathy Lysack, professor of occupational therapy and gerontology at Wayne State University.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
Tyler Wertz, 18, and his 16-year old brother Austin Tucker, fight, tease, love and support each other like most brothers do. Unlike most brothers, however, they share the same uncertain future—both have heart assist devices keeping them alive while they struggle with a debilitating disease. As young boys, Tyler and Austin were diagnosed with Becker's Muscular Dystrophy, a disease that slowly weakens the arms and legs and damages the heart.
› Verified 8 days ago
| Provider Name | Podiatry Plus Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366518664 PECOS PAC ID: 9537058961 Enrollment ID: O20040313000322 |
News Archive
Tobacco-related disease kills more people worldwide than any other single factor. To help address this problem, the University of California, Riverside has received six grants from the University of California Tobacco-Related Disease Research Program (TRDRP), the most TRDRP grants the campus has received in any year.
Record numbers of soldiers are returning from Iraq and Afghanistan with serious spinal cord injuries (SCI). Medical advancements can help heal their physical wounds, but little is known about how these veterans re-engage with their communities and rebuild meaningful lives. "How do they transition back to family and community life? How do they adjust to their physical impairments? And how do they reconfigure their homes, their work and their lives?" asked Cathy Lysack, professor of occupational therapy and gerontology at Wayne State University.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
Tyler Wertz, 18, and his 16-year old brother Austin Tucker, fight, tease, love and support each other like most brothers do. Unlike most brothers, however, they share the same uncertain future—both have heart assist devices keeping them alive while they struggle with a debilitating disease. As young boys, Tyler and Austin were diagnosed with Becker's Muscular Dystrophy, a disease that slowly weakens the arms and legs and damages the heart.
› Verified 8 days ago
| Provider Name | Elgin Foot & Ankle Center, S.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1639270663 PECOS PAC ID: 6002854569 Enrollment ID: O20050425000593 |
News Archive
Tobacco-related disease kills more people worldwide than any other single factor. To help address this problem, the University of California, Riverside has received six grants from the University of California Tobacco-Related Disease Research Program (TRDRP), the most TRDRP grants the campus has received in any year.
Record numbers of soldiers are returning from Iraq and Afghanistan with serious spinal cord injuries (SCI). Medical advancements can help heal their physical wounds, but little is known about how these veterans re-engage with their communities and rebuild meaningful lives. "How do they transition back to family and community life? How do they adjust to their physical impairments? And how do they reconfigure their homes, their work and their lives?" asked Cathy Lysack, professor of occupational therapy and gerontology at Wayne State University.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
Tyler Wertz, 18, and his 16-year old brother Austin Tucker, fight, tease, love and support each other like most brothers do. Unlike most brothers, however, they share the same uncertain future—both have heart assist devices keeping them alive while they struggle with a debilitating disease. As young boys, Tyler and Austin were diagnosed with Becker's Muscular Dystrophy, a disease that slowly weakens the arms and legs and damages the heart.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carolyn Kelly, DPM 396 Remington Blvd Ste 370, Bolingbrook, IL 60440-4302 Ph: (630) 418-6601 | Carolyn Kelly, DPM 396 Remington Blvd Ste 370, Bolingbrook, IL 60440-4302 Ph: (630) 418-6601 |
News Archive
Tobacco-related disease kills more people worldwide than any other single factor. To help address this problem, the University of California, Riverside has received six grants from the University of California Tobacco-Related Disease Research Program (TRDRP), the most TRDRP grants the campus has received in any year.
Record numbers of soldiers are returning from Iraq and Afghanistan with serious spinal cord injuries (SCI). Medical advancements can help heal their physical wounds, but little is known about how these veterans re-engage with their communities and rebuild meaningful lives. "How do they transition back to family and community life? How do they adjust to their physical impairments? And how do they reconfigure their homes, their work and their lives?" asked Cathy Lysack, professor of occupational therapy and gerontology at Wayne State University.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
Tyler Wertz, 18, and his 16-year old brother Austin Tucker, fight, tease, love and support each other like most brothers do. Unlike most brothers, however, they share the same uncertain future—both have heart assist devices keeping them alive while they struggle with a debilitating disease. As young boys, Tyler and Austin were diagnosed with Becker's Muscular Dystrophy, a disease that slowly weakens the arms and legs and damages the heart.
› Verified 8 days ago
Dr. Ronald P Pieroni, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 469 N Bolingbrook Dr, Bolingbrook, IL 60440 Phone: 630-378-0100 Fax: 630-378-0108 | |
Mrs. Debra Ruth Onvejiaka, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 406 West Boughton Road, Suite C, Bolingbrook, IL 60440 Phone: 630-972-1006 Fax: 630-759-8900 | |
Family Foot And Ankle Care, P.c. Podiatrist Medicare: Medicare Enrolled Practice Location: 550 E Boughton Rd Ste 195, Bolingbrook, IL 60440 Phone: 630-739-6610 Fax: 630-410-2482 | |
Aaron K Kim, DPM Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 396 Remington Blvd Ste 141, Bolingbrook, IL 60440 Phone: 630-418-6601 Fax: 866-512-8061 | |
Jeffrey M Mackler, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 454 W Boughton Rd, Suite A Jeffrey M Mackler Dpm, Bolingbrook, IL 60440 Phone: 630-759-4411 Fax: 630-759-6063 | |
Aaron Kim Dpm S.c Podiatrist Medicare: Medicare Enrolled Practice Location: 396 Remington Blvd, Bolingbrook, IL 60440 Phone: 630-418-6601 Fax: 866-512-8061 | |
Bolingbrook Foot Specialists Ltd Podiatrist Medicare: Medicare Enrolled Practice Location: 454 W Boughton Road, Bolingbrook, IL 60440 Phone: 630-759-4411 Fax: 630-759-6063 |